Highlights from our inaugural STAT Summit

We just wrapped up our first STAT Summit, and here are a couple of highlights: 

• On the future of bionic limbs: “If we lived in a future world in which you could replace your limbs and they’re as good or better as if you replaced your biological limb, would you be upset if you lost your biological limb? No, you wouldn't,” said Hugh Herr of the MIT Media Lab, who is the subject STAT’s feature-length documentary, “Augmented.” 
• On Biogen’s decision to pursue an Alzheimer’s drug targeting amyloid: "We didn't think that amyloid as a drug target had been adequately tested,” said Dr. Al Sandrock, chief medical officer at Biogen. “We believe in amyloid as a target because of the human genetics.” 
• On the FDA's struggle to regulate CBD: “We don’t know what happens if you take CBD every day for a year or we don't know what happens if you’re pregnant or breastfeeding,” said Dr. Amy Abernethy, principal deputy commissioner of the FDA. “We don’t know about CBD for people who are older in life or have other medical conditions.”

For a more thorough look at what happened at the event, check out #STATSummit on Twitter.